Sökning: onr:"swepub:oai:gup.ub.gu.se/108616" >
A phase 2 multiple ...
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
-
Salloway, S (författare)
-
Sperling, R (författare)
-
Gilman, S (författare)
-
visa fler...
-
Fox, N C (författare)
-
- Blennow, Kaj, 1958 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Raskind, M (författare)
-
Sabbagh, M (författare)
-
Honig, L S (författare)
-
Doody, R (författare)
-
van Dyck, C H (författare)
-
Mulnard, R (författare)
-
Barakos, J (författare)
-
Gregg, K M (författare)
-
Liu, E (författare)
-
Lieberburg, I (författare)
-
Schenk, D (författare)
-
Black, R (författare)
-
Grundman, M (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: Neurology. - 1526-632X. ; 73:24, s. 2061-70
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms. CONCLUSIONS: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status. Classification of evidence: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Psykiatri (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Psychiatry (hsv//eng)
Nyckelord
- Aged
- Alzheimer Disease
- diagnosis
- drug therapy
- genetics
- psychology
- Antibodies
- Monoclonal
- administration & dosage
- adverse effects
- Apolipoprotein E4
- genetics
- Biological Markers
- cerebrospinal fluid
- Brain
- pathology
- Brain Edema
- chemically induced
- diagnosis
- Cognition
- drug effects
- Dose-Response Relationship
- Drug
- Female
- Heterozygote
- Humans
- Magnetic Resonance Imaging
- Male
- Severity of Illness Index
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Salloway, S
-
Sperling, R
-
Gilman, S
-
Fox, N C
-
Blennow, Kaj, 19 ...
-
Raskind, M
-
visa fler...
-
Sabbagh, M
-
Honig, L S
-
Doody, R
-
van Dyck, C H
-
Mulnard, R
-
Barakos, J
-
Gregg, K M
-
Liu, E
-
Lieberburg, I
-
Schenk, D
-
Black, R
-
Grundman, M
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Psykiatri
- Artiklar i publikationen
-
Neurology
- Av lärosätet
-
Göteborgs universitet